GRTS vs. OTLK, BLUE, SGMO, LIFE, OMGA, PASG, VIGL, CRIS, ALVR, and CVM
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Outlook Therapeutics (OTLK), bluebird bio (BLUE), Sangamo Therapeutics (SGMO), aTyr Pharma (LIFE), Omega Therapeutics (OMGA), Passage Bio (PASG), Vigil Neuroscience (VIGL), Curis (CRIS), AlloVir (ALVR), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.
Outlook Therapeutics (NASDAQ:OTLK) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
Outlook Therapeutics presently has a consensus price target of $46.43, indicating a potential upside of 514.90%. Gritstone bio has a consensus price target of $5.33, indicating a potential upside of 595.26%. Given Outlook Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gritstone bio is more favorable than Outlook Therapeutics.
Outlook Therapeutics has higher earnings, but lower revenue than Gritstone bio. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Outlook Therapeutics has a net margin of 0.00% compared to Outlook Therapeutics' net margin of -926.13%. Outlook Therapeutics' return on equity of -232.42% beat Gritstone bio's return on equity.
Outlook Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Outlook Therapeutics received 14 more outperform votes than Gritstone bio when rated by MarketBeat users. Likewise, 70.32% of users gave Outlook Therapeutics an outperform vote while only 69.31% of users gave Gritstone bio an outperform vote.
11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 5.3% of Outlook Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Gritstone bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Gritstone bio had 4 more articles in the media than Outlook Therapeutics. MarketBeat recorded 11 mentions for Gritstone bio and 7 mentions for Outlook Therapeutics. Gritstone bio's average media sentiment score of 0.60 beat Outlook Therapeutics' score of -0.50 indicating that Outlook Therapeutics is being referred to more favorably in the media.
Summary
Gritstone bio beats Outlook Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Gritstone bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
Related Companies and Tools
